Vincent Fernando

Amgen Q1 2009 Performance Analysis: Shares Likely Present Compelling Value

It would depend on to what degree. It is likely to generate revenue and income, its just a matter of how much. Thus a negative scenario for the drug would be that maybe it doesn't break $1bn in annual revenue. Depending on how Enbrel and Aranesp continue to perform, this could mean no growth or even slight earnings contraction from AMGN for a year or two until more of the pipeline can help out.